Covid JN.1 Subvariant: Former AIIMS Director Discusses Increased Transmissibility and More
Covid JN.1 Subvariant: India has identified 25 cases of the JN.1 subvariant, a ‘variant of interest’ according to the World Health Organization. Amidst a surge in Covid cases in the country, fueled by the new JN.1 subvariant, former AIIMS director and senior pulmonologist, Dr. Randeep Guleria, emphasized on Saturday that the JN.1 subvariant is indeed more transmissible and is gradually gaining dominance. However, he reassured that it is not causing severe infections or leading to hospitalizations.
Dr. Guleria stated, “It is more transmissible, spreading more rapidly, and gradually becoming a dominant variant. It is causing more infections but the data also suggests that it is not causing severe infections or hospitalizations. Most of the symptoms are predominantly in the upper airways, like fever, cough, cold, sore throat, running nose, and body aches,” as reported by the news agency ANI.
Furthermore, Dr. Guleria explained that since the new variant is a lineage of Omicron, a vaccine developed for Omicron will be effective against this subvariant as well.
“We require a vaccine that encompasses a broader spectrum of the virus due to the multitude of mutations it has undergone. JN.1 is a sub-lineage of Omicron. Therefore, a vaccine developed against Omicron will be effective against this variant as well. However, we need more data to ascertain the current immunity levels in the population and the protection afforded by previous vaccinations. Based on this information, a decision can be made regarding the necessity of a new vaccine that covers the currently circulating strain. This evaluation needs to be a regular practice, given the continuously evolving nature of variants,” he stated.
India has identified 25 cases of the JN.1 subvariant, categorized as a ‘variant of interest’ by the World Health Organization. According to reports, 19 cases of JN.1 have been reported in Goa, four in Rajasthan, and one each in Kerala and Maharashtra.
SYMPTOMS OF JN.1 SUB-VARIANT:
- Runny nose
- Sore throat
- Abdominal pain and diarrhea